BRCASCAN™
A comprehensive genetic test for BRCA1/2 and other key HRR-related genes
BRCAscan™ analyzes 26 key genes associated with homologous recombination repair (HRR) pathways, including BRCA1/BRCA2, and ERBB2 to inform treatment decisions such as PARP inhibitors selection and assess genetic predisposition to breast, ovary, prostate and pancreatic cancers.
WHO IS IT FOR
- Individuals with a family history of BRCA1 or BRCA2 mutations
- Breast cancer patients with one or more of the following conditions:
- Early onset breast cancer diagnosed before age 45
- Family history of breast or/and ovarian cancer
- Triple negative breast cancer diagnosed at age 60 or younger
- Bilateral breast cancer diagnosed at age 50 or younger with two or more primary lesions
- HER2-negative metastatic breast cancer
- Male breast cancer patients
- Patients with advanced or recurrent ovarian cancer
- Patients with hereditary breast and ovarian cancer syndrome (HBOC)
- Patients with two or more types of cancer
- Patients with metastatic prostate cancer
- Patients with metastatic pancreatic cancer
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
